This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Szepeshazi, K. Articles by Halmos, G. Search for Related Content PubMed PubMed Citation Articles by Szepeshazi, K. Articles by Halmos, G.

Antagonists of GHRH Decrease Production of GH and IGF-I in MXT Mouse Mammary Cancers and Inhibit Tumor Growth

Endocrine, Polypeptide and Cancer Institute (K.S., A.V.S., P.A., K.G., F.H., A.F., J.L.V., G.H.), Veterans Affairs Medical Center, New Orleans, Louisiana 70112; and Department of Medicine (K.S., A.V.S., A.F., J.L.V., G.H.), Tulane University School of Medicine, New Orleans, Louisiana 70112

Address all correspondence and requests for reprints to: Dr. Andrew V. Schally, Endocrine, Polypeptide, and Cancer Institute, VA Medical Center, 1601 Perdido Street, New Orleans, Louisiana 70112-1262.

The involvement of IGF-I in mammary carcinogenesis is well established, but the role of GH, as an autocrine growth factor for breast cancers is poorly understood. The goal of our study was to investigate whether antagonists of GHRH can interfere with the effects of GH and IGF-I in MXT mouse mammary cancers. GHRH antagonists JV-1–36 and JV-1–38 inhibited growth of estrogen-independent MXT mouse mammary cancers in vivo, producing about 50% reduction in tumor volume (P < 0.05). This growth inhibition was associated with a decrease in cell proliferation and an increase in apoptosis in MXT cancers. RIA and RT- PCR analyses showed that the concentrations of GH and IGF-I and the levels of mRNA for GH and IGF-I in MXT tumors were reduced by the therapy with GHRH antagonists. Messenger RNA for GH receptors was also decreased. In vitro, the proliferation of MXT cancer cells was strongly stimulated by GH and less effectively by IGF-I, indicating that both GH and IGF-I may act as growth factors for this mammary carcinoma. GHRH antagonist JV-1–38 inhibited the autonomous growth of MXT cells and the proliferation induced by IGF-I or GH and diminished ³H-thymidine-incorporation stimulated by IGF-I and GH. These findings and a sustained increase in cyclin B2 concentrations in the cells shown by immunoblotting indicate that JV-1–38 causes a block at the end of the G₂ phase of cell cycle. Our results demonstrate that GHRH antagonists decrease the local production of both GH and IGF-I in MXT mouse mammary cancers, the resulting growth inhibition being the consequence of reduced cell proliferation and increased apoptosis.

This article has been cited by other articles:

				V. Pandey, J. K. Perry, K. M. Mohankumar, X.-J. Kong, S.-M. Liu, Z.-S. Wu, M. D. Mitchell, T. Zhu, and P. E. Lobie Autocrine Human Growth Hormone Stimulates Oncogenicity of Endometrial Carcinoma Cells Endocrinology, August 1, 2008; 149(8): 3909 - 3919. [Abstract] [Full Text] [PDF]

				Q. Shen, D. D. Lantvit, Q. Lin, Y. Li, K. Christov, Z. Wang, T. G. Unterman, R. G. Mehta, and S. M. Swanson Advanced Rat Mammary Cancers Are Growth Hormone Dependent Endocrinology, October 1, 2007; 148(10): 4536 - 4544. [Abstract] [Full Text] [PDF]

				S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel PNAS, February 6, 2007; 104(6): 1943 - 1946. [Abstract] [Full Text] [PDF]

				B. S. Emerald, Y. Chen, T. Zhu, Z. Zhu, K.-O. Lee, P. D. Gluckman, and P. E. Lobie {alpha}CP1 Mediates Stabilization of hTERT mRNA by Autocrine Human Growth Hormone J. Biol. Chem., January 5, 2007; 282(1): 680 - 690. [Abstract] [Full Text] [PDF]

				S. Mukhina, D. Liu, K. Guo, M. Raccurt, S. Borges-Bendris, H. C. Mertani, and P. E. Lobie Autocrine Growth Hormone Prevents Lactogenic Differentiation of Mouse Mammary Epithelial Cells Endocrinology, April 1, 2006; 147(4): 1819 - 1829. [Abstract] [Full Text] [PDF]

				G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone PNAS, July 26, 2005; 102(30): 10628 - 10633. [Abstract] [Full Text] [PDF]

				J. B. Engel, G. Keller, A. V. Schally, G. L. Toller, K. Groot, A. Havt, P. Armatis, M. Zarandi, J. L. Varga, and G. Halmos Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3614 - 3621. [Abstract] [Full Text] [PDF]

				E. E. Spangenburg SOCS-3 Induces Myoblast Differentiation J. Biol. Chem., March 18, 2005; 280(11): 10749 - 10758. [Abstract] [Full Text] [PDF]

				G. L. Toller, J. E. Horvath, A. V. Schally, G. Halmos, J. L. Varga, K. Groot, D. Chism, and M. Zarandi Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors PNAS, October 19, 2004; 101(42): 15160 - 15165. [Abstract] [Full Text] [PDF]

				J. L. Varga, A. V. Schally, J. E. Horvath, M. Kovacs, G. Halmos, K. Groot, G. L. Toller, Z. Rekasi, and M. Zarandi Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10 PNAS, February 10, 2004; 101(6): 1708 - 1713. [Abstract] [Full Text] [PDF]

				Z. Szereday, A. V. Schally, J. L. Varga, C. A. Kanashiro, F. Hebert, P. Armatis, K. Groot, K. Szepeshazi, G. Halmos, and R. Busto Antagonists of Growth Hormone-Releasing Hormone Inhibit the Proliferation of Experimental Non-Small Cell Lung Carcinoma Cancer Res., November 15, 2003; 63(22): 7913 - 7919. [Abstract] [Full Text] [PDF]

				G. Halmos, A. V. Schally, T. Czompoly, M. Krupa, J. L. Varga, and Z. Rekasi Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Human Prostate Cancer J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4707 - 4714. [Abstract] [Full Text] [PDF]

				H. Kiaris, A. V. Schally, R. Busto, G. Halmos, S. Artavanis-Tsakonas, and J. L. Varga Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs PNAS, January 1, 2002; (2002) 12590999. [Abstract] [Full Text] [PDF]

				H. Kiaris, A. V. Schally, R. Busto, G. Halmos, S. Artavanis-Tsakonas, and J. L. Varga Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs PNAS, January 8, 2002; 99(1): 196 - 200. [Abstract] [Full Text] [PDF]